Home > Publications Database > Continued dysfunction of capillary pericytes promotes no-reflow after experimental stroke in vivo. > print

001     268500
005     20240403131605.0
024 7 _ |a 10.1093/brain/awad401
|2 doi
024 7 _ |a pmid:38153327
|2 pmid
024 7 _ |a 0006-8950
|2 ISSN
024 7 _ |a 1460-2156
|2 ISSN
024 7 _ |a altmetric:158386980
|2 altmetric
037 _ _ |a DZNE-2024-00246
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Shrouder, Joshua James
|0 0000-0003-4845-2228
|b 0
245 _ _ |a Continued dysfunction of capillary pericytes promotes no-reflow after experimental stroke in vivo.
260 _ _ |a Oxford
|c 2024
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710419553_24479
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Incomplete reperfusion of the microvasculature ('no-reflow') after ischaemic stroke damages salvageable brain tissue. Previous ex vivo studies suggest pericytes are vulnerable to ischaemia and may exacerbate no-reflow, but the viability of pericytes and their association with no-reflow remains under-explored in vivo. Using longitudinal in vivo two-photon single-cell imaging over 7 days, we showed that 87% of pericytes constrict during cerebral ischaemia and remain constricted post reperfusion, and 50% of the pericyte population are acutely damaged. Moreover, we revealed ischaemic pericytes to be fundamentally implicated in capillary no-reflow by limiting and arresting blood flow within the first 24 h post stroke. Despite sustaining acute membrane damage, we observed that over half of all cortical pericytes survived ischaemia and responded to vasoactive stimuli, upregulated unique transcriptomic profiles and replicated. Finally, we demonstrated the delayed recovery of capillary diameter by ischaemic pericytes after reperfusion predicted vessel reconstriction in the subacute phase of stroke. Cumulatively, these findings demonstrate that surviving cortical pericytes remain both viable and promising therapeutic targets to counteract no-reflow after ischaemic stroke.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a cerebral ischaemia
|2 Other
650 _ 7 |a ischaemic stroke
|2 Other
650 _ 7 |a no-reflow
|2 Other
650 _ 7 |a pericytes
|2 Other
650 _ 7 |a reperfusion
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Stroke
|2 MeSH
650 _ 2 |a Pericytes: physiology
|2 MeSH
650 _ 2 |a Brain Ischemia
|2 MeSH
650 _ 2 |a Ischemic Stroke
|2 MeSH
650 _ 2 |a Cerebral Infarction
|2 MeSH
700 1 _ |a Calandra, Gian-Marco
|0 P:(DE-2719)9001033
|b 1
|u dzne
700 1 _ |a Filser, Severin
|0 P:(DE-2719)2810523
|b 2
|u dzne
700 1 _ |a Varga, Daniel Peter
|b 3
700 1 _ |a Besson-Girard, Simon
|b 4
700 1 _ |a Mamrak, Uta
|b 5
700 1 _ |a Dorok, Maximilian
|b 6
700 1 _ |a Bulut-Impraim, Buket
|b 7
700 1 _ |a Seker, Fatma Burcu
|b 8
700 1 _ |a Gesierich, Benno
|0 P:(DE-2719)9001112
|b 9
|u dzne
700 1 _ |a Laredo, Fabio
|b 10
700 1 _ |a Wehn, Antonia Clarissa
|b 11
700 1 _ |a Khalin, Igor
|b 12
700 1 _ |a Bayer, Patrick
|b 13
700 1 _ |a Liesz, Arthur
|0 0000-0002-9069-2594
|b 14
700 1 _ |a Gökce, Ozgun
|0 P:(DE-2719)9002754
|b 15
|u dzne
700 1 _ |a Plesnila, Nikolaus
|0 P:(DE-2719)9000853
|b 16
773 _ _ |a 10.1093/brain/awad401
|g Vol. 147, no. 3, p. 1057 - 1074
|0 PERI:(DE-600)1474117-9
|n 3
|p 1057 - 1074
|t Brain
|v 147
|y 2024
|x 0006-8950
856 4 _ |u https://pub.dzne.de/record/268500/files/DZNE-2024-00246%20SUP.zip
856 4 _ |u https://pub.dzne.de/record/268500/files/DZNE-2024-00246%20SUP2.zip
856 4 _ |u https://pub.dzne.de/record/268500/files/DZNE-2024-00246_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/268500/files/DZNE-2024-00246_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:268500
|p VDB
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-2719)9001033
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810523
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 9
|6 P:(DE-2719)9001112
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 15
|6 P:(DE-2719)9002754
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 16
|6 P:(DE-2719)9000853
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRAIN : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b BRAIN : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-2719)1040180
|k LMF
|l Light Microscopy Facility (CRFS-LMF)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1040180
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21